BioPharma Services Announces Expansion into Late-Stage Patient Trials and Integration with HEALWELL's Artificial Intelligence Platform Capabilities to Become a Full-Service Next Generation CRO

In This Article:

  • HEALWELL's subsidiary, BioPharma Services, is expanding into late-stage patient trials through the integration of Canadian Phase Onward, a dedicated clinical research site built within the framework of HEALWELL's Polyclinic Family and Specialty Medicine Facility.

  • This strategic integration is a significant milestone, enhancing BioPharma's ability to manage clinical trials across all phases of drug development and making the business a full-service Contract Research Organization. The move also supports HEALWELL's broader vision of building out clinical research capabilities and leveraging synergies across its business lines to drive growth and innovation in healthcare.

  • Biopharma will also be integrating with HEALWELL AI's leading edge data science and Artificial Intelligence platform to help advance research and development, disease detection and patient identification capabilities to support expedited patient trials.

  • Biopharma has completed over 2,200 clinical trials since inception with approximately 250 pharma clients, globally. This includes 4 of the top 25 largest pharmaceutical companies in the world.

Toronto, Ontario--(Newsfile Corp. - September 19, 2024) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF)("HEALWELL" or the "Company"), a healthcare technology company focused on AI and data science for preventative care, is pleased to announce its subsidiary, BioPharma Services Inc. ("BioPharma"), a leading Contract Research Organization ("CRO") specializing in early-phase clinical trials, is expanding into late stage patient trials through the integration of Canadian Phase Onward ("CPO"), a dedicated clinical research site built within the framework of HEALWELL's Polyclinic Family and Specialty Medicine Facility ("Polyclinic"). As the research arm of Polyclinic, CPO plays a pivotal role in facilitating patient enrolment and trial execution. This strategic integration is a significant milestone, enhancing BioPharma's ability to manage clinical trials across all phases of drug development and making the business a full-service CRO. The move also supports HEALWELL's broader vision of building out clinical research capabilities and leveraging synergies across its business lines to drive growth and innovation in healthcare.

Dr. Alexander Dobranowski, CEO of HEALWELL, commented, "BioPharma is an industry leader in early phase trials, and integrating them with our CPO division immediately leverages our synergies to create a more robust and complete end-to-end platform for life science customers. Given HEALWELL's access to significant patient populations, we have a unique opportunity to leverage our AI capabilities to efficiently find at-risk patients in need of access to clinical research. BioPharma is our clinical research engine, and has a strong competency and track record in first conducting early-stage trials in drug development, followed by CPO, which expands BioPharma's abilities into late-stage patient trials. Through these integrations, HEALWELL can now leverage AI to participate meaningfully across all stages of drug development, bringing immense value potential to at-risk patients and life science partners."